Bispecific ADCs: Overcoming Tumor Resistance in Oncology

The oncology sector is experiencing a massive leap forward as Bispecific ADCs hit the clinic. While first-generation antibody-drug conjugates proved the viability of targeted chemotherapy, they frequently encountered roadblocks like tumor heterogeneity and acquired drug resistance. Today, clinical-stage developers are engineering these highly sophisticated, multi-mechanism molecules designed specifically to conquer these limitations and deliver unprecedented survival benefits. [1]

Engineering Bispecific ADCs for 2026

The defining characteristic of modern Bispecific ADCs is the abandonment of the traditional single-target architecture. To increase the therapeutic window, researchers are combining dual-antigen targets with advanced bioconjugation technologies to prevent the cancer from adapting to the treatment.

How Bispecific ADCs Utilize Dual-Payloads

Tumors frequently develop resistance to a single cytotoxic mechanism. To combat this, companies like Alphamab Oncology are pioneering “2-in-1” designs. In March 2026, the China CDE officially accepted the IND application for JSKN021, one of the most anticipated Bispecific ADCs targeting both EGFR and HER3. [2] It utilizes glycan-specific conjugation to attach two distinct payloads—a Topoisomerase I inhibitor and MMAE—to a single antibody.

Site-Specific Designs

Systemic toxicity remains a hurdle, which is why developers prioritize linker stability. NextCure is advancing LNCB74, targeting B7-H4. Utilizing a glucuronidase-cleavable linker paired with an MMAE payload, LNCB74 ensures the toxin is only released within the tumor microenvironment. [3]

The Clinical Pipeline for Bispecific ADCs

The following table highlights the most anticipated Bispecific ADCs and dual-payload milestones.

References

• [1] OncLive: FDA Approves Blenrep Return
• [2] PR Newswire: Alphamab Oncology JSKN021 IND
• [3] ClinicalTrials.gov: NextCure LNCB74 Phase 1
• [4] Whitehawk Therapeutics Technology